Novavax (NVAX) Hisse Fiyat
Novavax Fiyat
Gelir, son 19 yılda yıllık bileşik %33,4 artarak 1,12 Md USD seviyesine ulaştı. Novavax şirketinde net marj %39,2 seviyesinde bulunuyor; birkaç yıl önceki %-152,1 seviyesine göre yükseldi. Analistler 18,00 USD medyan fiyat hedefi belirliyor; bu, güncel fiyatın %78,6 üzerinde bir seviyeye işaret ediyor. 15 analistten 10 tanesi hisse için alım öneriyor — genel konsensüs: Al.
Novavax hisse senedi fiyatı
Bu verilere Eulerpool API üzerinden ulaşın
Ayda 100.000 ücretsiz istek · kredi kartı yok
Novavax iş modeli ve hisse analizi
Novavax hakkında sık sorulan sorular
Novavax Inc is primarily active within the biotechnology and pharmaceutical industries.
The main competitors of Novavax Inc in the market are companies like Moderna, Pfizer, and Johnson & Johnson.
The business model of Novavax Inc revolves around developing innovative vaccines to address infectious diseases. Novavax is a biotechnology company that focuses on the discovery, development, and commercialization of vaccines for various viral infections. With a particular focus on respiratory diseases, including influenza and respiratory syncytial virus (RSV), Novavax utilizes cutting-edge technologies to create vaccines that stimulate protective immune responses. The company's approach includes the use of recombinant nanoparticle vaccine technology, which enables the production of vaccine antigens that closely mimic targeted viruses. Novavax strives to provide advanced vaccine solutions to combat prevalent and emerging infectious diseases worldwide.
Novavax Inc. is a leading biotechnology company focused on the development of innovative vaccines. Founded in 1987, Novavax has a rich history of scientific excellence and groundbreaking research. The company is committed to addressing urgent global health challenges and has made significant advancements in the field of vaccine development. Novavax has pioneered the use of recombinant nanoparticle vaccine technology and has successfully produced vaccine candidates for a range of infectious diseases, including respiratory syncytial virus (RSV), influenza, and COVID-19. With its strong research capabilities and dedicated team, Novavax continues to strive for transformative solutions in public health through its pioneering vaccine technologies.
Novavax Inc has achieved several significant milestones. One of the key achievements includes the development of a proprietary recombinant nanoparticle vaccine technology platform called Matrix-M. This innovative platform has facilitated the creation of multiple vaccine candidates targeting viral diseases. Novavax Inc has also successfully conducted clinical trials and achieved positive results for various vaccines, including those targeting respiratory syncytial virus (RSV) and influenza. Furthermore, the company has collaborated with renowned organizations, such as the Coalition for Epidemic Preparedness Innovations (CEPI) and the Bill & Melinda Gates Foundation, demonstrating its recognition and partnerships within the industry.
Novavax Inc is primarily present in multiple countries and regions. The company has a global presence and operates in various key markets. Some of the primary countries and regions where Novavax Inc is actively engaged include the United States, United Kingdom, Canada, Europe, and Australia. With its innovative and cutting-edge approach to vaccine development, Novavax Inc aims to offer its healthcare solutions to a wide range of international markets. The company's commitment to expanding its presence ensures that its groundbreaking medical technologies reach people across different countries and regions, fostering better health outcomes worldwide.
Novavax Inc represents values of innovation, dedication, and collaboration in the biotechnology industry. With a corporate philosophy focused on developing novel vaccines to prevent infectious diseases, Novavax aims to improve global health outcomes. Their commitment to scientific excellence and rigorous research enables them to address evolving public health challenges. Novavax Inc strives to make a positive impact by developing safe and effective vaccines, leveraging their technological expertise and diverse partnerships. Through their tireless efforts, Novavax Inc aims to provide innovative solutions to protect communities worldwide, solidifying their position as a leading biotech company.
Analistler şu anda Novavax hissesi için ortalama 18,00 USD hedef fiyat belirliyor (medyan: 18,00 USD); bu, son fiyata göre +78,6 % anlamına gelir. Konsensüs 15 analist notuna dayanır.
15 analist şu anda Novavax hissesini değerlendiriyor: 10 al, 2 tut, 3 sat öneriyor. 2026 için analistler Novavax şirketinin 383,71 M USD gelir ve -0,52 USD hisse başına kâr üretmesini bekliyor.
Güncel döviz kuruyla Novavax hissesi 9,00 EUR (10,08 USD) seviyesindedir.
Novavax hissesi (NVAX) 8 borsada işlem görür, bunlar arasında: NASDAQ (NVAX), London (0A3S.L), SIX (Zürich) (NVV1.SW), XETRA (NVV1.F), München (NVV1.MU), Düsseldorf (NVV1.DU), Hamburg (NVV1.HM).
Novavax Inc. is a biopharmaceutical company specializing in the development of innovative vaccines and treatments for a variety of infectious diseases. The company was founded in 1987 and is headquartered in Gaithersburg, Maryland, USA.
beklenen'nin Novavax hasılatı 383,71 M USD'dir. Bu rakam, mevcut finansal verilere dayanmakta ve şirketin iş performansını yansıtmaktadır.
beklenen'nin Novavax karı -90,50 M USD'dir. Net kar, tüm giderleri düştükten sonra şirketin kârlılığını gösterir.
Novavax'nin Fiyat/Kazanç (F/K) oranı şu anda -19,28'dir. F/K oranı, cari hisse fiyatını hisse başına kazançla karşılaştırır ve yatırımcıların Novavax hisse senedinin değerlemesini değerlendirmelerine yardımcı olur.
Novavax'nin Fiyat/Satış (F/S) oranı şu anda 4,55'dir. F/S oranı, pazar kapitalizasyonunu yıllık gelirle karşılaştırır ve Novavax hisse senedinin değerleme metriği olarak hizmet eder.
Novavax'nin Eulerpool Kalite Puanı 5/10'dur.
Novavax'nin ISIN'i US6700024010'dir. ISIN (Uluslararası Menkul Kıymetler Kimlik Numarası), menkul kıymetler için küresel olarak benzersiz bir tanımlayıcıdır.
Novavax'nin WKN'i A2PKMZ'dir. WKN (Wertpapierkennnummer), menkul kıymetleri tanımlamak için kullanılan altı haneli bir Alman kimlik numarasıdır.
Novavax'nin ticker'ı NVAX'dir. Ticker sembolü, Novavax hisseleri borsada işlem görmek için kullanılır.
Novavax Hissesi
Novavax Emsaller Grubu
Novavax Ticker
Novavax FIGI
Novavax'nin tüm temel göstergeleri ve derinlemesine analizi
Novavax hissesine yönelik aktienanalizimiz, satış, kar, P/E oranı, P/S oranı, EBIT gibi önemli mali kriterleri içermekte olup, dividende bilgilerini de ele almaktadır. Ayrıca, hisseler, piyasa değeri, borçlar, özsermaye ve Novavax şirketin yükümlülükleri gibi konuları incelemekteyiz. Bu konular hakkında daha detaylı bilgilere ihtiyacınız varsa, web sitemizin alt sayfalarında kapsamlı analizler sunuyoruz: